ArteraAI

A leading precision medicine company, ArteraAI develops AI-enabled tests to help personalize therapy for cancer patients.

[ArteraAI @arteraAI]

Dr. Daniel Spratt on Artera’s Post‑RP test:

“[It] uses clinical and pathologic features + digital pathology, running AI to help ID patients at low vs high risk of recurrence and metastasis.”

Thanks @UroTimes + Hannah Clarke for the feature.

https://t.co/81ShDfFaKT

#ArteraAI

[ArteraAI @arteraAI]

What does it take to bring AI into real clinical care?

Great discussion from #ASCOGU on how tools like the #ArteraAI Prostate Test are already shaping decisions today, with potential across cancers.

Watch the interview: https://t.co/jiNm31J6e2

#PrecisionMedicine

[ArteraAI @arteraAI]

AI is continuing to reshape #breast cancercare, from screening to personalized treatment insights.

Interesting look at how these technologies may improve outcomes for women over 50: https://t.co/clBwmHz55f

#AIinHealthcare #ArteraAI #PrecisionMedicine

[ArteraAI @arteraAI]

We're excited to be featured as one of the key trends to watch at #ASCO2026! AI is making a splash in precision oncology, from drug discovery to screening to risk stratification.

https://t.co/BKwcJQ4JpD

[ArteraAI @arteraAI]

We’re looking forward to connecting with clinicians and partners and continuing conversations around AI-powered precision cancer care at these events next month.

If you’ll be attending, reach out to us to set up a meeting: https://t.co/iwumS0Qufu

#ArteraOnTheGo

[ArteraAI @arteraAI]

For low- and favorable intermediate-risk #prostatecancer patients, Artera’s #ActiveSurveillance Insights help guide active surveillance decisions with:

✓ No tissue consumption
✓ Easy to interpret results
✓ 1–2 day turnaround

#PrecisionOncology #ArteraAI

[ArteraAI @arteraAI]

What is AI actually “seeing” in digital pathology?

Dr. Amol Shetty explores the biological pathways underlying AI-based biomarkers in #prostatecancer and how AI-detected patterns may align with known disease biology.

Learn more: https://t.co/hOVR8NGR6d

#ArteraAI

[ArteraAI @arteraAI]

#ASCO26 is almost here, and we’re proud to be sharing multiple Artera presentations across both breast and prostate cancer.

Excited to continue conversations around multimodal AI and personalized #oncology care in Chicago.

#BreastCancer #ProstateCancer #ArteraAI #ArteraOnTheGo

[ArteraAI @arteraAI]

That's a wrap on #AUA26

Grateful for the conversations, connections, and continued momentum around AI-powered precision care in #urology. Thanks to everyone who connected with the Artera team.

#ProstateCancer #ArteraOnTheGo

[Diagnexia @diagnexia]

We're exhibiting at BAUS 2026 in London with our partners @ArteraAI

Together we're bringing the first AI multimodal risk stratification tool for localised prostate cancer to the UK, predicting 10-year metastasis risk using standard biopsy slides, with results in hours.

The only tool of its kind recommended by NCCN in the USA. Now available here.

See you there!

#BAUS2026 #ProstateCancer #Diagnexia #AIinOncology

[ArteraAI @arteraAI]

How can we better stratify risk in localized prostate cancer?

CHHiP trial analysis highlighted by Anna Wilkins points to the role of multimodal AI in delivering more precise, biology-driven insights.

Learn more: https://t.co/D0iemLYKJa

#ProstateCancer #AIinHealthcare

[ArteraAI @arteraAI]

Great conversations at the Executive War College event last month.

Thank you to everyone who joined Amanda Lowe and Jennifer Archer to discuss integrating AI into pathology and the evolving regulatory and reimbursement landscape.

#DigitalPathology #AIinHealthcare #ArteraAI

[ArteraAI @arteraAI]

Clarity matters in clinical decision-making.

Grateful to hear how the #ArteraAI Prostate Test is supporting real-world practice.

#ProstateCancer #AIinHealthcare

[ArteraAI @arteraAI]

We’re heading to the APG Spring Conference in San Diego this month.

Looking forward to connecting with healthcare leaders on value-based care, population health, and the role of AI in oncology.

#APG2026 #ValueBasedCare #ArteraOnTheGo

[ArteraAI @arteraAI]

If you treat localized #prostatecancer, consider incorporating the #ArteraAI Prostate Test into multidisciplinary decisions, especially around treatment intensification.

It augments, not replaces, clinical judgment.

Read more in this @Medscape article: https://t.co/y8bktHv6zI

[ArteraAI @arteraAI]

Next stop: #ASCO26

We’re excited to join leaders across #oncology to discuss the latest research, innovation, and the evolving role of AI in clinical care.

See you there.

#PrecisionOncology #DigitalHealth #ArteraOnTheGo

[UroToday.com @urotoday]

Genomic classifiers and AI for personalizing #ProstateCancer radiation therapy. @drjefstathiou @MassGenBrigham joins @neerajaiims @huntsmancancer to discuss the use of genomic classifiers and AI-based tools in personalizing radiation therapy for prostate cancer. #WatchNow on UroToday > https://t.co/WSgUZx48Eg #APCCC26 @Decipher_VCYT @APCCC_Lugano @arteraAI

[Laura Heacock, MD @heacockmd]

Pathology AI-based prognostic tests continue to roll out. @arteraAI has one of the best known FDA-cleared/CE marked prostate cancer prognostic tests and CPT III coding for it.

They have just received FDA clearance for their new breast product that predicts distant metastasis in early-stage, hormone-positive, HER2- breast cancer based on pathology slide analysis.

1) This makes FDA clearance easier for similar products in the breast space -- there are other good companies working in this space.

2) If they manage a CPTIII code for this one too, there is a valid reimbursement pathway for breast path AI predictive tests.

https://t.co/UUYmjxDtO5

[ArteraAI @arteraAI]

Cancer care isn’t just about survival, it’s about quality of life.

In this piece, Artera’s VP of Medical Science, Calvin Chao, explores how AI-enabled pathology is helping personalize treatment decisions.

Read more: https://t.co/WJv8B9kgZK

#ProstateCancer #ArteraAI

[ArteraAI @arteraAI]

We have received FDA clearance for #ArteraAI Breast, expanding our AI platform into #breastcancer.

A key step in bringing personalized, data-driven insights to more patients.

Learn more: https://t.co/XHpelJuUPL

#AIinHealthcare #PrecisionMedicine

[ArteraAI @arteraAI]

We’re heading to #AUA2026 in Washington, DC this month.

Looking forward to connecting with the urology community and continuing the conversation around precision #prostatecancer care.

#ArteraOnTheGo